Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered coaching aims to tame metabolic syndrome

NCT ID NCT07410325

Disease control Sponsor: National University Health System, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called LIGHTER-MetS that combines health coaching with an AI-powered app to help people with metabolic syndrome eat better and lower their heart risk. About 316 adults aged 21-65 with metabolic syndrome will join. They will work with a health coach for 3 months and use the eTRIP© app to track meals and activity. The goal is to see if this approach improves self-regulation of eating and reduces cardiovascular risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LIGHTER-MetS program (health coaching plus eTRIP© app)
What this could lead to
If successful, this program could offer an effective, scalable way for people with metabolic syndrome to improve their eating habits and lower their heart disease risk.
What could go wrong
This is a relatively small, early-stage study (316 participants) testing a behavioral intervention, so results may not apply broadly. Success depends on participants consistently using the app and coaching.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 316 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. are between 21 to 65 years of age; 2. have a waist circumference ≥90 cm in men and ≥80 cm in women; 3. have 2 or more of the following to be classified as having metabolic syndrome: * triglyceride level of ≥1.7 mmol/L or on specific treatment for this lipid abnormality; * high density lipoprotein (HDL) cholesterol \<1.03 mmol/L in men, and \<1.29 mmol/L in women, or on specific treatment for this lipid abnormality; * blood pressure of ≥130/85 mmHg or on treatment of previously diagnosed hypertension; * fasting blood glucose level of ≥ 5.6 mmol/L or previously diagnosed type 2 diabetes; 4. are not receiving other structured lifestyle modification programs; 5. consent to audio-recording; 6. English speaking and literate. Exclusion Criteria: 1. underwent or are scheduled for metabolic surgery within 1 year; 2. are pregnant or planning for pregnancy at the time of recruitment; 3. are unable to speak English; 4. do not own a smartphone; and 5. are unable to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome Metabolic syndrome (METS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National University of Singapore

    RECRUITING

    Singapore, 117597, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.